Document Detail

Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
MedLine Citation:
PMID:  8350953     Owner:  NLM     Status:  MEDLINE    
One hundred and one patients undergoing anticancer chemotherapy due to hematologic malignancy were retrospectively divided into two groups: 67 patients were treated with ceftriaxone plus amikacin, receiving once daily (od) 2-4 g ceftriaxone, 1-1.5 g amikacin (those without a peripheral or central venous catheter) and 34 patients with central or peripheral venous catheter (CPVC) receiving ceftizidime 2 g three times daily (tid) plus amikacin 0.5 g tid i.v. Both groups were similar as to their isolated pathogens, localization of infection, and basic diagnoses of hematologic malignancies. There was no significant difference in efficacy between ceftriaxone plus amikacin versus ceftazidime plus amikacin, but the toxicity was lower in once daily ceftriaxone plus amikacin group.
V Krcméry; A Danisovicová; L Drgona; S Spánik; P Fuchsberger; S Korec; J Svec
Related Documents :
22993363 - A preliminary study of single intraperitoneal administration of paclitaxel followed by ...
16573743 - Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen ...
6827343 - Intraventricular hemorrhage from ruptured aneurysm. retrospective analysis of 91 cases.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Neoplasma     Volume:  40     ISSN:  0028-2685     ISO Abbreviation:  Neoplasma     Publication Date:  1993  
Date Detail:
Created Date:  1993-09-13     Completed Date:  1993-09-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0377266     Medline TA:  Neoplasma     Country:  CZECHOSLOVAKIA    
Other Details:
Languages:  eng     Pagination:  103-5     Citation Subset:  IM    
Department of Clinical Oncology, Postgraduate Medical School, Bratislava, Slovakia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amikacin / adverse effects,  therapeutic use*
Antineoplastic Agents / therapeutic use
Bacterial Infections / drug therapy*,  etiology
Candidiasis / drug therapy,  etiology
Catheterization, Central Venous
Catheterization, Peripheral
Ceftazidime / adverse effects,  therapeutic use*
Ceftriaxone / adverse effects,  therapeutic use*
Drug Therapy, Combination / adverse effects,  therapeutic use
Hearing / drug effects
Kidney / drug effects
Leukemia / complications,  drug therapy
Lymphoma / complications,  drug therapy
Neutropenia / complications*,  etiology
Retrospective Studies
Reg. No./Substance:
0/Antineoplastic Agents; 37517-28-5/Amikacin; 73384-59-5/Ceftriaxone; 78439-06-2/Ceftazidime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modulation of leukosialin (sialophorin, CD43 antigen) on the cell surface of human hematopoietic cel...
Next Document:  Erythrocyte glutathione peroxidase in patients with colon cancer.